basal ganglia diseases

Summary

Summary: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.

Top Publications

  1. ncbi Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis
    Cheng Wang
    Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China
    Nat Genet 44:254-6. 2012
  2. pmc Association between a novel mutation in SLC20A2 and familial idiopathic basal ganglia calcification
    Yang Zhang
    Research Center for Medical Genomics, Key Laboratory of Medical Cell Biology, Ministry of Education, College of Basic Medical Science, China Medical University, Shenyang, China
    PLoS ONE 8:e57060. 2013
  3. ncbi Mineralization of the basal ganglia: implications for neuropsychiatry, pathology and neuroimaging
    Manuel F Casanova
    Department of Psychiatry, Medical College of Georgia, Augusta, GA 30912, USA
    Psychiatry Res 121:59-87. 2003
  4. ncbi Diagnostic criteria for corticobasal syndrome: a comparative study
    Robert Mathew
    Neurosciences Research Australia, and University of New South Wales, Sydney, Australia
    J Neurol Neurosurg Psychiatry 83:405-10. 2012
  5. pmc Extrapyramidal side-effects of antipsychotics in a randomised trial
    Del D Miller
    University of Iowa Carver College of Medicine, Iowa City, IA 52242 1000, USA
    Br J Psychiatry 193:279-88. 2008
  6. ncbi New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis
    Stefan Leucht
    Klinik und Poliklinik fur Psychiatrie und Psychotherapie der Technischen Universitat Munchen, Klinikum rechts der Isar, Munchen, Germany
    Lancet 361:1581-9. 2003
  7. pmc A wide spectrum of clinical and brain MRI findings in patients with SLC19A3 mutations
    Kenichiro Yamada
    Department of Genetics, Institute for Developmental Research, Aichi Human Service Center, Aichi, Japan
    BMC Med Genet 11:171. 2010
  8. ncbi 2q37 as a susceptibility locus for idiopathic basal ganglia calcification (IBGC) in a large South Tyrolean family
    Claudia Beu Volpato
    Institute of Genetic Medicine, European Academy Bozen Bolzano EURAC, 39100 Bolzano, Bozen, Italy
    J Mol Neurosci 39:346-53. 2009
  9. pmc Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3
    Wen Qi Zeng
    Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Charlestown, MA 02129 2000, USA
    Am J Hum Genet 77:16-26. 2005
  10. ncbi Fahr's syndrome presenting with pure and progressive presenile dementia
    P J Modrego
    Av da de la Ilustración 12, C34, ES 50012, Zaragoza, Spain
    Neurol Sci 26:367-9. 2005

Detail Information

Publications234 found, 100 shown here

  1. ncbi Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis
    Cheng Wang
    Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China
    Nat Genet 44:254-6. 2012
    ..Our results implicate altered phosphate homeostasis in the etiology of IBGC...
  2. pmc Association between a novel mutation in SLC20A2 and familial idiopathic basal ganglia calcification
    Yang Zhang
    Research Center for Medical Genomics, Key Laboratory of Medical Cell Biology, Ministry of Education, College of Basic Medical Science, China Medical University, Shenyang, China
    PLoS ONE 8:e57060. 2013
    ..We propose that the regional expression pattern of SLC20A1 and SLC20A2 might explain the unique calcification pattern observed in FIBGC patients...
  3. ncbi Mineralization of the basal ganglia: implications for neuropsychiatry, pathology and neuroimaging
    Manuel F Casanova
    Department of Psychiatry, Medical College of Georgia, Augusta, GA 30912, USA
    Psychiatry Res 121:59-87. 2003
    ..The authors suggest that these metabolic abnormalities may link basal ganglia mineralization to psychotic symptomatology...
  4. ncbi Diagnostic criteria for corticobasal syndrome: a comparative study
    Robert Mathew
    Neurosciences Research Australia, and University of New South Wales, Sydney, Australia
    J Neurol Neurosurg Psychiatry 83:405-10. 2012
    ..There are no well-established criteria for patients with corticobasal syndrome. The authors have attempted to clarify this area by comparing and applying three sets of well-known criteria (from Toronto, the Mayo Clinic and Cambridge)...
  5. pmc Extrapyramidal side-effects of antipsychotics in a randomised trial
    Del D Miller
    University of Iowa Carver College of Medicine, Iowa City, IA 52242 1000, USA
    Br J Psychiatry 193:279-88. 2008
    ..There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs...
  6. ncbi New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis
    Stefan Leucht
    Klinik und Poliklinik fur Psychiatrie und Psychotherapie der Technischen Universitat Munchen, Klinikum rechts der Isar, Munchen, Germany
    Lancet 361:1581-9. 2003
    ..We aimed to establish whether the new drugs induce fewer EPS than low-potency conventional antipsychotics...
  7. pmc A wide spectrum of clinical and brain MRI findings in patients with SLC19A3 mutations
    Kenichiro Yamada
    Department of Genetics, Institute for Developmental Research, Aichi Human Service Center, Aichi, Japan
    BMC Med Genet 11:171. 2010
    ..Homozygous or compound heterozygous mutations in SLC19A3 cause two distinct clinical phenotypes, biotin-responsive basal ganglia disease and Wernicke's-like encephalopathy. Biotin and/or thiamin are effective therapies for both diseases...
  8. ncbi 2q37 as a susceptibility locus for idiopathic basal ganglia calcification (IBGC) in a large South Tyrolean family
    Claudia Beu Volpato
    Institute of Genetic Medicine, European Academy Bozen Bolzano EURAC, 39100 Bolzano, Bozen, Italy
    J Mol Neurosci 39:346-53. 2009
    ..Electronic supplementary material. The online version of this article (doi:10.1007/s12031-009-9287-3) contains supplementary material, which is available to authorized users...
  9. pmc Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3
    Wen Qi Zeng
    Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Charlestown, MA 02129 2000, USA
    Am J Hum Genet 77:16-26. 2005
    ....
  10. ncbi Fahr's syndrome presenting with pure and progressive presenile dementia
    P J Modrego
    Av da de la Ilustración 12, C34, ES 50012, Zaragoza, Spain
    Neurol Sci 26:367-9. 2005
    ..The clinical and radiological features of our patient point to this uncommon form of dementia...
  11. ncbi Biotin-responsive basal ganglia disease: case report and review of the literature
    T I El-Hajj
    Department of Internal Medicine American University of Beirut, Beirut, Lebanon
    Neuropediatrics 39:268-71. 2008
    ..Since our case showed differences with those in the literature, it might represent a new entity or a milder form of the same entity...
  12. ncbi Biotin-responsive basal ganglia disease-linked mutations inhibit thiamine transport via hTHTR2: biotin is not a substrate for hTHTR2
    Veedamali S Subramanian
    Dept of Medicine, University of California, Irvine, USA
    Am J Physiol Cell Physiol 291:C851-9. 2006
    ..These results cast doubt on the most parsimonious explanation for the BBGD phenotype, namely that hTHTR2 is a physiological biotin transporter...
  13. ncbi Biotin-responsive basal ganglia disease: a treatable and reversible neurological disorder of childhood
    P S Bindu
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India
    J Child Neurol 24:750-2. 2009
    ..Only few cases have been reported earlier in literature. We report a case of biotin-responsive basal ganglia disease suspected clinically, corroborated by neuroimaging and a dramatic response to biotin therapy...
  14. ncbi Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials
    Harald Scherk
    Department of Psychiatry and Psychotherapy, Georg August University Goettingen, Goettingen, Germany
    Arch Gen Psychiatry 64:442-55. 2007
    ..Meta-analyses addressing the use of SGAs in the treatment of acute mania are lacking...
  15. ncbi What is and what is not 'Fahr's disease'
    Bala V Manyam
    Department of Neurology, Scott and White Clinic, Plummer Movement Disorders Center, The Texas A and M University System Health Science Center College of Medicine, Temple, TX 76508, USA
    Parkinsonism Relat Disord 11:73-80. 2005
    ..Calcium and other mineral deposits cannot be linked to a single chromosomal locus. Further genetic studies to identify the chromosomal locus for the disease are in progress...
  16. ncbi Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations
    Rabab Debs
    Federation of Nervous System Diseases, Assistance Publique Hopitaux de Paris, Hopital de la Salpetriere, Universite Pierre et Marie Curie, Paris Cedex 13, France
    Arch Neurol 67:126-30. 2010
    ..To report the first 2 European cases of biotin-responsive basal ganglia disease and novel SLC19A3 mutations...
  17. ncbi Biotin-responsive basal ganglia disease: a novel entity
    P T Ozand
    Department of Paediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
    Brain 121:1267-79. 1998
    ..Although its aetiology is unknown, it is important to recognize this disease, since its symptoms may be reversed and the progression of its clinical course prevented simply by providing biotin...
  18. ncbi A laser microprobe mass analysis of trace elements in brain mineralizations and capillaries in Fahr's disease
    C Bouras
    Department of Psychiatry, University of Geneva School of Medicine, Chene Bourg, Switzerland
    Acta Neuropathol 92:351-7. 1996
    ....
  19. ncbi Basal ganglia calcification and psychotic symptoms in the very old
    Svante Ostling
    The Sahlgrenska Academy at Goteborg University, Institute of Clinical Neuroscience, Psychiatry Section, Unit for Neuropsychiatric Epidemiology, Sahlgrenska University Hospital, Goteborg, Sweden
    Int J Geriatr Psychiatry 18:983-7. 2003
    ..Basal ganglia calcification (BGC) is associated with psychotic symptoms in young and middle-aged patient samples...
  20. ncbi [Asymptomatic familial basal ganglia calcification with autosomal dominant inheritance: a family report]
    N Yamada
    Department of Pediatrics, Ube Kyoritsu Hospital, Ube, Yamaguchi
    No To Hattatsu 32:515-9. 2000
    ..These facts suggest our pedigree is a new type of familial basal ganglia calcification with autosomal dominant inheritance...
  21. ncbi Natural killer cell proliferation and circulating cytokines in patients with bilateral basal ganglia calcification
    T Morishima
    Department of Health Science, Nagoya University School of Medicine, Japan
    Eur J Neurol 9:521-5. 2002
    ..In summary, NK cell propagation and circulating cytokines, particularly tumor necrosis factor-alpha, may be involved in the etiology of basal ganglia calcification...
  22. ncbi Analysis of gene expression pattern and neuroanatomical correlates for SLC20A2 (PiT-2) shows a molecular network with potential impact in idiopathic basal ganglia calcification ("Fahr's disease")
    R J Galdino da Silva
    Keizo Asami Laboratory, Federal University of Pernambuco, Av Prof Moraes Rego 1235, Cidade Universitaria, Recife, Pernambuco 50670 901, Brazil
    J Mol Neurosci 50:280-3. 2013
    ..Lastly, these co-expression networks suggest additional further candidate genes for FIBGC...
  23. pmc Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification
    Sandy Chan Hsu
    Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    Neurogenetics 14:11-22. 2013
    ..Non-perfect segregation patterns of predicted deleterious variants highlight the challenges of phenotypic assessment in this condition with highly variable clinical presentation...
  24. pmc Identification of a locus on chromosome 14q for idiopathic basal ganglia calcification (Fahr disease)
    D H Geschwind
    Neurogenetics Program, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Am J Hum Genet 65:764-72. 1999
    ..3-cM region by a recombination observed in a patient with probable affected status. The age at onset appeared to be decreasing by an average of >20 years with each transmission, which is consistent with genetic anticipation...
  25. ncbi Evaluation of regional cerebral blood flow in fahr disease with schizophrenia-like psychosis: a case report
    Masaru Shoyama
    Department of Neuropsychiatry, Wakayama Medical University, Kimiidera, Wakayama, Japan
    AJNR Am J Neuroradiol 26:2527-9. 2005
    ..Such perfusion abnormalities may reflect psychotic symptoms, including auditory hallucinations and delusions, which suggests a disruption of the cortico-subcortical neural circuits in psychosis...
  26. ncbi Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification
    Gael Nicolas
    Inserm U1079, University Hospital and Faculty of Medicine, Rouen
    Neurology 80:181-7. 2013
    ..To identify a new idiopathic basal ganglia calcification (IBGC)-causing gene...
  27. ncbi Idiopathic bilateral strio-pallido-dentate calcinosis (Fahr's disease): a case report and review of the literature
    Sani A Abubakar
    Department of Medicine, Ahmadu Bello University Teaching Hospital Zaria, Nigeria
    Ann Afr Med 11:234-7. 2012
    ..This review presents a case of bilateral strio-pallido-dentate calcification; it also affirms the fact that Fahr's disease could present with hyperkinetic movement disorder (chorea) in our setting...
  28. pmc Subacute dementia and imaging correlates in a case of Fahr's disease
    T Benke
    University Clinic of Neurology, Innsbruck, Austria
    J Neurol Neurosurg Psychiatry 75:1163-5. 2004
    ..This case indicates that FD may cause exclusively behavioural alterations and that the associated hypometabolism in certain frontal areas is closely related to the clinical picture...
  29. ncbi A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder
    Charles L Bowden
    Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 66:111-21. 2005
    ..To evaluate the efficacy and tolerability of quetiapine monotherapy versus placebo for the treatment of mania associated with bipolar disorder...
  30. ncbi Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease)
    J R M Oliveira
    Neurogenetics Program, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Neurology 63:2165-7. 2004
    ..The authors found evidence against linkage to IBGC1 in five of the six families supporting previous preliminary studies demonstrating genetic heterogeneity in familial IBGC...
  31. ncbi A case of idiopathic basal ganglia calcification associated with membranoproliferative glomerulonephritis
    Yoshiki Tsuchiya
    Nephrology Center, Toranomon Hospital, Japan
    Intern Med 50:2351-6. 2011
    ..This is the first report of IBGC with bilateral and symmetrical cerebral calcification accompanied by membranoproliferative glomerulonephritis resulting in end-stage renal failure...
  32. ncbi Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, and Department of Psychiatry, McGill University, Montreal, QC, Canada, H3A 1A1
    Schizophr Res 76:247-65. 2005
    ..ESRS specificity was investigated through two different approaches, path analyses and ANCOVA PANSS factors changes, which found that ESRS measurement of drug-induced EPS is valid and discriminative from psychiatric symptoms...
  33. ncbi Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial
    Laksami N Yatham
    University of British Columbia, Vancouver, Canada
    Br J Psychiatry 182:141-7. 2003
    ..Few double-blind trials have examined the efficacy of a combination of a mood stabiliser and an atypical antipsychotic in acute mania...
  34. ncbi Alien hand syndrome
    I Biran
    Department of Neurology and the Center for Cognitive Neuroscience, University of Pennsylvania, Philadelphia 19104, USA
    Arch Neurol 61:292-4. 2004
    ..This article outlines the origins of the terminology used in describing this syndrome, early observations, and studies regarding its functional neuroanatomy...
  35. ncbi The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia
    J C Gomez
    Eli Lilly and Company, Madrid, Spain
    J Clin Psychiatry 61:335-43. 2000
    ..Results of controlled clinical trials should be confirmed through safety and effectiveness studies in nonselected patient cohorts treated according to routine clinical practice...
  36. ncbi Asymmetrical alien hands in corticobasal degeneration
    David B Fitzgerald
    Department of Neurology, University of Florida, Gainesville, Florida, USA
    Mov Disord 22:581-4. 2007
    ..Mitgehen is often associated with frontal dysfunction, but avoidance response and levitation are often associated with parietal dysfunction...
  37. ncbi Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms
    Cüneyt Güzey
    Department of Clinical Pharmacology, St Olav University Hospital, Trondheim, Norway
    Eur J Clin Pharmacol 63:233-41. 2007
    ..Little is known about the influence of polymorphisms of the dopamine and serotonin system on the risk for extrapyramidal symptoms (EPS) during treatment with antipsychotic drugs...
  38. ncbi Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety
    Gary S Sachs
    Bipolar Research Program, Department of Psychiatry, Massachusetts General Hospital, 50 Staniford Street, Suite 580, Boston, MA 02114, USA
    Am J Psychiatry 159:1146-54. 2002
    ..The study assessed the efficacy and safety of risperidone as an adjunctive agent to mood stabilizers in the treatment of acute mania...
  39. pmc Sporadic corticobasal syndrome due to FTLD-TDP
    Maria Carmela Tartaglia
    Memory and Aging Center, Department of Neurology, University of California, 1207, 350 Parnassus Ave, Ste 905, San Francisco, CA 94143 1207, USA
    Acta Neuropathol 119:365-74. 2010
    ..These findings confirm that FTLD-TDP should be included in the pathological differential diagnosis for sporadic CBS...
  40. ncbi Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials
    Patrizia A Cavazzoni
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 67:107-13. 2006
    ..The present analysis retrospectively examined olanzapine clinical trial data for incidence of treatment-emergent EPS in patients with either schizophrenia or bipolar disorder...
  41. ncbi CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study
    Camilla J Kobylecki
    Research Institute of Biological Psychiatry, Copenhagen University Hospital, Sct Hans Hospital, Roskilde, Denmark
    Neuropsychobiology 59:222-6. 2009
    ..The impaired metabolic capacity of the PM genotype results in higher steady-state plasma concentrations at a given dose, thus increasing the risk of toxic effects from medication...
  42. ncbi Balancing efficacy and safety in treatment with antipsychotics
    Christoph U Correll
    Recognition and Prevention Program, Zucker Hillside Hospital, Queens, New York, USA
    CNS Spectr 12:12-20, 35. 2007
    ....
  43. ncbi Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study
    Diederik E Tenback
    Department of Psychiatry and Neuropsychology, Maastricht University, P O Box 616 DRT 10, 6200 MD Maastricht, The Netherlands
    Am J Psychiatry 163:1438-40. 2006
    ..This study examined whether extrapyramidal symptoms predict incidence of tardive dyskinesia 1 year later...
  44. ncbi A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania
    Paul E Keck
    Biological Psychiatry Program, Department of Psychiatry, University of Cincinnati College of Medicine, PO Box 670559, Cincinnati, OH 45267 0559, USA
    Am J Psychiatry 160:1651-8. 2003
    ..The authors compared the efficacy and safety of aripiprazole, a novel antipsychotic, to placebo for treatment of patients in an acute manic or mixed episode of bipolar disorder...
  45. ncbi Cognitive and motor assessment in autopsy-proven corticobasal degeneration
    R Murray
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Neurology 68:1274-83. 2007
    ..To investigate the clinical features of autopsy-proven corticobasal degeneration (CBD)...
  46. ncbi Safety and tolerability: how do newer generation "atypical" antipsychotics compare?
    Rajiv Tandon
    University of Michigan Medical Center, Ann Arbor, MI 48109 0120, USA
    Psychiatr Q 73:297-311. 2002
    ....
  47. ncbi Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia
    Laura Parkkinen
    Department of Neuroscience and Neurology, Kuopio University, 70211 Kuopio, Finland
    Ann Neurol 57:82-91. 2005
    ..Some neurologically unimpaired cases had a reasonable burden of alpha-synuclein pathology in both brainstem and cortical areas, suggesting that alpha-synuclein-positive structures are not definite markers of neuronal dysfunction...
  48. ncbi A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms
    P Gasso
    Department of Anatomic Pathology, Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain
    Pharmacogenomics J 9:404-10. 2009
    ..AP-induced EPS remains a serious public health problem. Our finding of a common SNP (rs167771) in the DRD3 gene provides a strong new candidate gene for risperidone-induced EPS...
  49. ncbi Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Child Adolesc Psychiatr Clin N Am 15:177-206. 2006
    ..This article presents an overview of SGA-related side effects in children and adolescents and strategies to monitor health outcomes effectively in youngsters receiving SGAs...
  50. ncbi Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina
    J A Sacristan
    Clinical Research Department, Lilly S A, Madrid, Spain
    Clin Ther 22:583-99. 2000
    ....
  51. ncbi Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
    Chul Lee
    Neuroscience Division, Eli Lilly and Company, Taipei, Taiwan
    Aust N Z J Psychiatry 40:437-45. 2006
    ..To examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone or typical antipsychotics in naturalistic settings...
  52. ncbi Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
    Hans Jurgen Moller
    Department of Psychiatry, University of Munich, Germany
    Int Clin Psychopharmacol 20:121-30. 2005
    ..Direct initiation of RLAI was effective and well tolerated. RLAI provides an advancement in the treatment options available for a wide range of patients requiring long-term antipsychotic therapy...
  53. ncbi Neurologic soft signs and olanzapine treatment in chronic schizophrenia
    Levent Sevincok
    J Clin Psychopharmacol 24:571-2. 2004
  54. ncbi Olanzapine treatment of residual positive and negative symptoms
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
    Am J Psychiatry 162:124-9. 2005
    ..The authors examined the comparative efficacy and safety of olanzapine and haloperidol in outpatients with partially responsive schizophrenia...
  55. ncbi The utility of intramuscular ziprasidone in the management of acute psychotic agitation
    Alan J Mendelowitz
    Department of Psychiatry, Albert Einstein University, Bronx, New York, USA
    Ann Clin Psychiatry 16:145-54. 2004
    ..This report focuses on the pharmacology, clinical efficacy, and tolerability of IM ziprasidone, and provides an overview of the utility of other commonly used antipsychotics in the management of acute psychotic agitation...
  56. ncbi Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia
    Donna J Lang
    VGH Research Pavilion, Centre for Complex Disorders, West 10th Ave, Room 211 828, Vancouver, British Columbia, Canada V5Z 1L8
    Am J Psychiatry 161:1829-36. 2004
    ..A follow-up study of patients with schizophrenia was conducted to examine change in striatal volumes and extrapyramidal symptoms after a change in medication...
  57. ncbi Risperidone plasma levels, clinical response and side-effects
    Michael Riedel
    Dept of Psychiatry and Psychotherapy, University of Munich, 80336 Munich, Germany
    Eur Arch Psychiatry Clin Neurosci 255:261-8. 2005
    ..We thus prospectively investigated risperidone serum concentrations in relation to clinical efficacy and side-effects and genotyped major CYP2D6 polymorphisms to determine their effect upon these parameters...
  58. ncbi Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine
    Benoit H Mulsant
    Western Psychiatric Institute and Clinic, Department of Psychiatry, Division of Geriatric Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Clin Psychiatry 65:1708-14. 2004
    ..Older individuals with dementia are highly sensitive to the effects of muscarinic receptor blockade...
  59. ncbi A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety
    A Elif Anil Yagcioglu
    Department of Psychiatry, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey
    J Clin Psychiatry 66:63-72. 2005
    ....
  60. ncbi Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia
    X S Ren
    Health Services Department, Center for the Assessment of Pharmaceutical Practices, Boston University School of Public Health, Boston, MA 07130, USA
    J Clin Pharm Ther 30:65-71. 2005
    ..Because EPS are often associated with the use of antipsychotics, anticholinergic agents are often indicated...
  61. ncbi Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study
    Antonio Ciudad
    Lilly Research Laboratories, 30 Avenida de la Industria, Alcobendas CP28108, Madrid, Spain
    Eur Psychiatry 19:358-65. 2004
    ..To evaluate the safety and tolerability of olanzapine in the treatment of elderly patients with schizophrenia...
  62. ncbi Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6
    Shingo Kakihara
    Department of Psychiatry, University Hospital of Occupational and Environmental Health, Kitaykushu, Fukuoka, Japan
    Int Clin Psychopharmacol 20:71-8. 2005
    ....
  63. ncbi Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness
    William G Honer
    Department of Psychiatry, University of British Columbia, Vancouver, Canada
    J Psychopharmacol 19:277-85. 2005
    ..In this group, family history and poor premorbid functioning appear to be associated with increased risk for movement disorders...
  64. ncbi Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes
    Delbert G Robinson
    Department of Psychiatry, The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Am J Psychiatry 163:2096-102. 2006
    ..The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders...
  65. ncbi Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial
    Shahin Akhondzadeh
    Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337, Iran
    Schizophr Res 90:179-85. 2007
    ..The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with chronic schizophrenia and anti-inflammatory therapies should be further investigated...
  66. ncbi [The use of atypical antipsychotics in the long-term care of schizophrenia]
    F Limosin
    Hopital Robert Debre, Reims, France
    Encephale 32:S1065-71. 2006
  67. ncbi Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study
    David Mamo
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Am J Psychiatry 164:1411-7. 2007
    ..The authors conducted a positron emission tomography (PET) study to characterize the simultaneous effects of aripiprazole at the D(2), 5-HT(2), and 5-HT(1A) receptors in patients with schizophrenia or schizoaffective disorder...
  68. ncbi Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome
    Joseph W Y Lee
    Graylands Hospital and School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia
    Ann Clin Psychiatry 19:9-16. 2007
    ..This case series study examines the hypothesis that neuroleptic malignant syndrome (NMS) is a heterogeneous condition including catatonic variants and non-catatonic pathological reactions to antipsychotics...
  69. ncbi An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms
    Kristina Timdahl
    AstraZeneca, Sodertalje, Sweden
    Hum Psychopharmacol 22:315-25. 2007
    ....
  70. ncbi Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks
    John M Kane
    The Zucker Hillside Hospital, 75 59 263 St, Glen Oaks, NY 11004, USA
    Schizophr Res 95:143-50. 2007
    ..This analysis examined symptomatic remission in acutely ill patients with schizophrenia receiving either aripiprazole or haloperidol for one year...
  71. ncbi Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation
    Vincenzo Villari
    Emergency Department, Psychiatric Emergency Service, S Giovanni Hospital, Corso Bramante 88, 10126 Turin, Italy
    Prog Neuropsychopharmacol Biol Psychiatry 32:405-13. 2008
    ..The aim of this study was to compare the effectiveness of three second generation antipsychotics (risperidone, olanzapine, quetiapine) versus haloperidol in the treatment of psychotic agitation for up to 72 h...
  72. ncbi A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial
    Emilio Sacchetti
    Department of Psychiatry, Brescia University School of Medicine, Brescia, Italy
    Schizophr Res 98:55-65. 2008
    ..In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents...
  73. ncbi [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]
    Szendi István
    SZTE Pszichiátriai Klinika, Szeged, Hungary
    Neuropsychopharmacol Hung 9:115-24. 2007
    ..Extrapyramidal symptoms of patients treated with olanzapine improved significantly better compared with those patients who received other antipsychotics and risperidone respectively...
  74. ncbi Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol
    Raisa Andrezina
    Department of Psychiatry, Riga Mental Health Care Centre, Tvaika Street 2, Riga, 1005, Latvia
    Psychopharmacology (Berl) 188:281-92. 2006
    ..This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder...
  75. ncbi Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study
    Kate X Zhong
    AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA
    J Clin Psychiatry 67:1093-103. 2006
    ..To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia...
  76. ncbi A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia
    Enrique Alvarez
    Department of Psychiatry, Hospital Santa Creu i Sant Pau, Barcelona, Spain
    J Clin Psychopharmacol 26:238-49. 2006
    ..To evaluate the efficacy of olanzapine compared with risperidone in negative symptoms, after 1 year of treatment, in schizophrenic outpatients with prominent negative symptoms...
  77. ncbi Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 101 Quarry Road 2122, Stanford, CA 94305, USA
    J Clin Psychiatry 66:638-41. 2005
    ..To compare the long-term efficacy and tolerability of oral quetiapine with those of intramuscular haloperidol...
  78. ncbi Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol
    Steven L Sayers
    Philadelphia Veterans Affairs Medical Center, University and Woodland Avenues, Philadelphia, PA 19104, USA
    J Nerv Ment Dis 193:379-86. 2005
    ..Important study limitations include a small sample size and high attrition rates. Larger controlled studies are necessary to determine optimal antipsychotic therapy for patients with schizophrenia and comorbid cocaine abuse...
  79. ncbi Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study
    Antonio Ciudad
    Lilly Research Laboratories, Avda de la Industria, 30, 28108 Alcobendas, Madrid, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 29:944-51. 2005
    ..This study investigated safety and effectiveness of olanzapine in monotherapy compared with conventional antipsychotics in treatment of acute inpatients with schizophrenia...
  80. ncbi Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release
    Akiko Matsui-Sakata
    Department of Medico Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
    Drug Metab Pharmacokinet 20:187-99. 2005
    ..The developed model incorporating endogenous dopamine release owing to 5-HT2A receptor inhibition may be useful for the prediction of antipsychotics-induced EPS...
  81. ncbi Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study
    Sylvia Park
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
    Br J Psychiatry 187:137-42. 2005
    ..The extent to which atypical antipsychotics have a lower incidence of extrapyramidal symptoms than typical antipsychotics has not been well-evaluated in community practice...
  82. ncbi Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss
    T H Andersen
    Psychiatric Research Unit, Frederiksborg General Hospital, Hillerød, Denmark
    Nord J Psychiatry 59:205-8. 2005
    ..In addition, we observed a medium weight reduction of 10.5 kg (range 1-20 kg)...
  83. ncbi Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia
    Alan Breier
    Lilly Research Laboratories, DC 2128, 1 Corporate Plaza, Indianapolis, IN 46285, USA
    Am J Psychiatry 162:1879-87. 2005
    ..The efficacy and safety of olanzapine were compared with those of ziprasidone...
  84. ncbi A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ont M5T 1R8, Canada
    Am J Psychiatry 163:396-401. 2006
    ..The present study used positron emission tomography (PET) to evaluate its dopamine D(2) binding profile at doses of 25, 50, or 75 mg administered every 2 weeks...
  85. ncbi The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial
    Y Lecrubier
    Pitié Salpétrière U 302 Hospital, Paris Cedex, France
    Acta Psychiatr Scand 114:319-27. 2006
    ..The aim of the study was to evaluate the efficacy of olanzapine (5 and 20 mg/day) over a 6-month period in chronic schizophrenic patients experiencing predominantly negative symptoms...
  86. ncbi Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers
    Juan Francisco Artaloytia
    Hospital Universitario 12 de Octobre, Madrid, Spain
    Am J Psychiatry 163:488-93. 2006
    ..The present study assessed observer-rated and self-rated negative symptoms produced by conventional and second-generation antipsychotics in healthy volunteers...
  87. ncbi A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia
    Victor Perez
    Department of Psychiatry, Hospital de la Sta Creu i Sant Pau, Barcelona CIBERSAM, Spain
    Int Clin Psychopharmacol 23:138-49. 2008
    ..In conclusion, quetiapine and risperidone had comparable effectiveness, but there were differences between treatments in their side effect profile...
  88. ncbi Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
    Istvan Bitter
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 28:173-80. 2004
    ..Olanzapine therefore presents a safe alternative in the treatment of refractory schizophrenia...
  89. ncbi Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study
    Víctor Rodríguez-Pérez
    Centro Residencial y Rehabilitador San Rafael, C Castro Riberas de Lea, 27260 Lugo, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 26:1055-62. 2002
    ..The aim of this study is to provide long-term data on the effectiveness and safety of olanzapine in a group of patients with severe refractory schizophrenia...
  90. ncbi Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study
    Lieuwe De Haan
    Academic Medical Center, University of Amsterdam Department of Psychiatry, The Netherlands
    Am J Psychiatry 160:303-9. 2003
    ..In addition, they sought preliminary evidence on whether subjective experience is better with low-dose olanzapine than with low-dose haloperidol...
  91. ncbi Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study
    Gil Zalsman
    Adolescent Inpatient Department, Geha Mental Health Center, Rabin Medical Center Sackler Faculty of Medicine, Tel Aviv University, Petah Tiqva, Israel
    J Child Adolesc Psychopharmacol 13:319-27. 2003
    ..In conclusion risperidone appears to be a safe, acceptably tolerated, and effective antipsychotic medication for the treatment of adolescent-onset schizophrenia...
  92. ncbi Comparative effectiveness of antipsychotic drugs
    Richard C Meibach
    Am J Psychiatry 160:589-90; author reply 592-3. 2003
  93. ncbi Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone
    Peter J Weiden
    Department of Psychiatry, Box 1203, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    J Clin Psychopharmacol 23:595-600. 2003
    ....
  94. ncbi Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation
    Yasuhiro Kaneda
    Psychopharmacology Division, Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA
    Int J Neuropsychopharmacol 6:247-52. 2003
    ..Our findings suggested that risperidone might improve psychosocial and motivation/energy QoL subscales, and increase prolactin without affecting the HPG axis hormones...
  95. ncbi Diurnal variations of extrapyramidal symptoms induced by haloperidol in schizophrenic subjects
    Carlos Torner
    Universidad Autonoma Metropolitana Xochimilco, Mexico
    Int J Neuropsychopharmacol 6:243-6. 2003
    ..The difference in the diurnal pattern of the haloperidol-induced side-effects, suggests that receptor-related mechanisms with a different circadian profile contribute to the induction of the extrapyramidal symptoms...
  96. ncbi An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
    Christopher D Carlson
    Eli Lilly and Company, Indianapolis, Ind, USA
    J Clin Psychiatry 64:898-906. 2003
    ....
  97. ncbi Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland
    H J Moller
    Psychiatric Clinic, Ludwig Maximilians University, Munich, Germany
    Eur Arch Psychiatry Clin Neurosci 247:291-6. 1997
    ..The optimal dose of risperidone, in terms of both efficacy and safety, was 4 mg/day. These results confirm the findings of the controlled trials of risperidone conducted in North America and the multinational trial...
  98. ncbi Pharmacological approaches to the management of schizophrenia
    Timothy J R Lambert
    Office for Psychiatric Evaluation and Educational Newmedia, Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Vic
    Med J Aust 178:S57-61. 2003
    ..The choice of particular agents for individual patients requires a balancing of efficacy and side effects. Medication is only one element of what should be an individualised comprehensive treatment plan for people with schizophrenia...
  99. ncbi Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, NC 27599 7160, USA
    Am J Psychiatry 160:1396-404. 2003
    ..This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial...
  100. ncbi A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study
    H J Moller
    Department of Psychiatry, Ludwig Maximilian University of Munich, Germany
    Eur Arch Psychiatry Clin Neurosci 245:45-9. 1995
    ..The relationship between shift in extrapyramidal symptoms and shift in negative symptoms failed to reach statistical significance; however, there was a clear tendency in the expected direction in both treatment groups...
  101. ncbi Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study
    Jean Pierre Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Center, Wards Island, NY 10035, USA
    J Clin Psychiatry 63:931-5. 2002
    ....

Research Grants62

  1. Scheduled and Responsive Brain Stimulation for the Treatment of Tourette Syndrome
    Michael S Okun; Fiscal Year: 2010
    ....
  2. Molecular Mechanisms Controlling Formation of Basal Ganglia Circuitry
    KENNETH J CAMPBELL; Fiscal Year: 2013
    ....
  3. Organization and Function of Striatal Microcircuits in Health and Disease
    ARYN HILARY GITTIS; Fiscal Year: 2012
    ..Together, all of these experiments will advance our understanding of the neural circuitry that underlies motor control and potentially identify new targets for disease therapy. ..
  4. Organization and Function of Striatal Microcircuits in Health and Disease
    ARYN HILARY GITTIS; Fiscal Year: 2013
    ..Together, all of these experiments will advance our understanding of the neural circuitry that underlies motor control and potentially identify new targets for disease therapy. ..
  5. PERIPHERAL AND CENTRAL POSTURAL DISORDERS IN THE ELDERLY
    FAY BAHLING HORAK; Fiscal Year: 2013
    ..abstract_text> ..
  6. Cortical contributions to basal ganglia disorders
    PETER STRICK; Fiscal Year: 2006
    ..abstract_text> ..
  7. Eye Movement Control: Cortical &Subcortical Mechanisms
    Paul W Glimcher; Fiscal Year: 2013
    ....
  8. Mechanisms of Deep Brain Stimulation
    JOEL SYNES PERLMUTTER; Fiscal Year: 2013
    ..These studies also have the potential to help refine DBS targeting, inform future development of new electrode design to shape current spread and improve programming strategies for optimal clinical benefit from STN DBS. ..
  9. NEURONAL PATHWAYS OF THE BASAL GANGLIA
    Hitoshi Kita; Fiscal Year: 2000
    ..The methods for the proposed study include: unit recording, intracellular recording and staining in both anesthetized animals and brain slice preparations. ..
  10. MOTOR FUNCTIONS AND FIBER CONNECTIONS OF PALLIDUM
    SAMUEL LILES; Fiscal Year: 1990
    ..However, the development of a coherent theory of the fundamental disorder in motor control of basal ganglia diseases in humans is limited in part due to an absence of knowledge of the normal physiological role of the basal ..
  11. Motor Learning in Parkinson's Disease
    M Ghilardi; Fiscal Year: 2002
    ....
  12. REGULATION OF LIMBIC EXCITABILITY
    Cheolsu Shin; Fiscal Year: 1992
    ....
  13. CRCNS: Neural Flow Networks in Songbirds
    ALEXANDER HARTEMINK; Fiscal Year: 2009
    ..This will enable scientists to better understand how neural anatomical networks are actively utilized and how that utilization evolves over time. ..
  14. CODING OF BEHAVIORAL SEQUENCES IN THE BASAL GANGLIA
    J Aldridge; Fiscal Year: 2001
    ..network properties related to the organization of behavioral sequences will lead to a better understanding of the pathophysiology of basal ganglia diseases and eventually contribute to better treatments for these brain disorders.
  15. Mapping Basal Ganglia Function During Motor Sequencing
    Vinod Menon; Fiscal Year: 2002
    ..Furthermore, the proposed research will aid in understanding and treating basal ganglia disorders, such as schizophrenia, ADHD, Huntington's disease, Parkinson's disease, and Tourette's syndrome. ..
  16. STRIATAL ORGANIZATION AND DOPAMINE RECEPTOR LOCALIZATION
    John Marshall; Fiscal Year: 2006
    ..The significance of this work derives both from its relevance to basal ganglia disorders such as Parkinson's disease and also because of its potential to elucidate the significance of the pallidostriatal circuitry. ..
  17. BASAL GANGLIA DISORDERS AND NEUROTRANSMITTER FUNCTION
    NORMAN WEINER; Fiscal Year: 1980
    ..The relationship between spontaneous activity and evoked responses in the electroencephalogram, excretion of dopamine metbolites and the development of tardive dyskinesias in man will be studied...
  18. Dissociation of motor deficits in learning tasks
    Rebecca Spencer; Fiscal Year: 2006
    ..abstract_text> ..
  19. TREATMENT OF EARLY ONSET SCHIZOPHRENIA SPECTRUM (TEOSS)
    Robert Findling; Fiscal Year: 2005
    ..This study will provide information about the comparative effectiveness of the most commonly used and representative antipsychotic drugs in youth with schizophrenia spectrum disorders. ..
  20. Depressoin in Alzheimer's Disease Study-2 (DIADS-2)
    Jacobo Mintzer; Fiscal Year: 2007
    ..abstract_text> ..
  21. COMT genotype and response to cognitive remediation in schizophrenia
    Jean Pierre Lindenmayer; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  22. The Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Weight...
    Robert Buchanan; Fiscal Year: 2008
    ..There should be direct evidence of efficacy and safety in these patients in order to provide truly effective treatments and further understanding of these disorders. [unreadable] [unreadable] [unreadable]..
  23. Clozapine Treatment of Schizophrenic Patients
    Robert Buchanan; Fiscal Year: 2006
    ..The study will provide new information on the clinical utility of adjunctive risperidone in treatment-resistant patients who fail to adequately respond to clozapine. ..
  24. Institute for Research Minority Training on Mental Health
    Jacobo Mintzer; Fiscal Year: 2007
    ..We expect this effort to be the incubator for a new generation of minority researchers dedicated to the study mental health and aging. ..
  25. Advanced Centers for Interventions and Services Research
    Robert Buchanan; Fiscal Year: 2007
    ....
  26. Apathy in Alzheimer's Disease Methylphenidate Trial
    Paul B Rosenberg; Fiscal Year: 2010
    ..This study aims to develop a new treatment for apathy in AD that could decrease its debilitating consequences and reduce patients'dependency on caregivers, providing well-deserved relief to patients and their loved ones. ..
  27. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 2001
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  28. Mechanisms of Long-Term Depression in the Striatum
    Anatol Kreitzer; Fiscal Year: 2005
    ..These studies will provide a framework for understanding how long-term changes in synaptic strength in the striatum are related to such health issues as addiction and neurodegenerative disease. ..
  29. ASYMMETRICALLY EXPRESSED GENES IN DEVELOPING CEREBRUM
    Daniel Geschwind; Fiscal Year: 2003
    ..abstract_text> ..
  30. Mutant Gene Identification in the Dystonic Rat
    Mark leDoux; Fiscal Year: 2008
    ..Patients with dystonia will be screened for mutations in the human homologue. These proposed studies will likely increase our understanding of both dystonia and olivocerebellar motor systems. ..
  31. NALTREXONE BLOCKADE OF NMDA
    John Krystal; Fiscal Year: 2002
    ..Thus, the blockade of the rewarding effects of ketamine by naltrexone may provide insight into an important mechanism underlying the psychopharmacology of ethanol and the treatment of alcoholism. ..
  32. CONTROL OF SPIKING IN BASAL GANGLIA OUTPUT NEURONS
    Dieter Jaeger; Fiscal Year: 2008
    ..By determining the details of input/ouput transformations at the single cell level we will be able to make important predictions to how alterations in this process can lead to changes in network processing. [unreadable] [unreadable]..
  33. COCAINE SENSITIZATION AND THE DOPAMINE TRANSPORTER
    NANCY ZAHNISER; Fiscal Year: 2008
    ..abstract_text> ..
  34. PREVENTING MORBIDITY IN FIRST EPISODE SCHIZOPHRENIA
    Delbert Robinson; Fiscal Year: 2008
    ..The findings will provided guidance to clinicians in the selection of the best medication for patients experiencing a first episode of illness, who have no prior treatment history to guide this choice. ..
  35. Bipolar Statistical Summit:Methodologies to Advance Long Term Intervention Trials
    Charles Bowden; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  36. NEUROPSYCHOLOGY OF DEMENTIA WITH LEWY BODIES
    TANIS FERMAN; Fiscal Year: 2009
    ..This has implications for symptom management, development of treatment options and for providing education and support to DLB patients and their caregivers. ..
  37. MULTIPLE FAMILY GROUPS FOR LATINOS WITH SCHIZOPHRENIA
    Alex Kopelowicz; Fiscal Year: 2003
    ..Academic and research activities will take place throughout the award period. ..
  38. Family Based Treatment of Early Childhood OCD
    Henrietta Leonard; Fiscal Year: 2004
    ..At the end of the study, a final revised, comprehensive, manualized treatment protocol would be completed which could be tested in large efficacy and effectiveness studies. ..
  39. BRAIN MRI & MRS CHANGES IN FIRST EPISODE SCHIZOPHRENIA
    Jeffrey Lieberman; Fiscal Year: 2004
    ..This study will provide important information about the clinical and neuropathological course of subgroups of schizophrenia and therapeutic strategies for early identification and intervention. ..
  40. RUPP-PI Project
    Michael Aman; Fiscal Year: 2006
    ..S.U. also plans two pilot studies: (a) a randomized clinical trial in 60 children with PDDs and severe ADHD behavior and (b) a study of ziprasidone in 30 children and adolescents with PDDs and highly irritable behaviors. ..
  41. ANTIPSYCHOTIC TREATMENT RESPONSE
    Del Miller; Fiscal Year: 2004
    ..This award will also serve as a mechanism by which the candidate can establish professional collaborative relationships with his mentors and provide him with the background for ongoing research leading to an independent research career. ..
  42. Fetal Alcohol Syndrome: Neuropsychological Assessment of Children
    SARAH MATTSON; Fiscal Year: 2007
    ..Clarification of these dissociations will help define the profile of weaknesses and strengths in children with heavy prenatal alcohol exposure and help identify core deficits in this population. ..
  43. METHYLPHENIDATE TREATMENT AND PRENATAL ALCOHOL EXPOSURE
    SARAH MATTSON; Fiscal Year: 2002
    ..Knowledge gained from this research will help to provide a more rational basis for the treatment of the well-documented attentional problems in these children. ..
  44. Symposium on Neuroimaging in Alcoholism
    John Krystal; Fiscal Year: 2003
    ..A call for abstracts also will bring forward names and ideas from other groups that might be added to the main program. Young Investigator travel scholarships will be considered. ..
  45. Influence of subthalamic nucleus on striatal dopamine
    Thomas Wichmann; Fiscal Year: 2004
    ..These studies will provide insight into the role of the STN-SNc interaction under normal and parkinsonian conditions and will help to understand the mechanisms of action of neurosurgical treatments aimed at SIN in parkinsonian patients. ..
  46. Neuroanatomy of social Function in FTD
    Katherine Rankin; Fiscal Year: 2005
    ..abstract_text> ..
  47. Promoting Adherence to Treatment in Schizophrenia
    Alex Kopelowicz; Fiscal Year: 2006
    ..abstract_text> ..
  48. INTERVENING AT PRODROMAL STAGES OF PSYCHOSIS
    Diana Perkins; Fiscal Year: 2004
    ..The results of this study will guide the design of future intervention studies and are anticipated to provide pilot data for an R01 testing novel treatment strategies with patients in the prodromal stage of psychotic illness. ..
  49. Folate in Schizophrenia
    Donald C Goff; Fiscal Year: 2010
    ..This will be the first adequately-powered study to assess efficacy and identify predictors of response. ..
  50. Synaptic integration in the deep cerebellar nuclei
    Dieter Jaeger; Fiscal Year: 2007
    ..These studies are expected to generate important insights into cerebellar function and the mechanisms underlying cerebellar movement disorders. [unreadable] [unreadable]..
  51. PAR04-122 Satellite Animal Facility Construction Project
    Jeffrey Lieberman; Fiscal Year: 2009
    ..The design will meet all NIH guidelines for the care and use of laboratory animals and health and safety regulations for staff. ..
  52. TETRAHYDROISOQUINOLINES AND PARKINSON'S DISEASE
    Mark leDoux; Fiscal Year: 2006
    ..Evolution may have not provided neurons with mechanisms to prevent accumulation of these by-products of normal metabolism and, as a consequence, susceptible neuronal populations may slowly undergo apoptotic death in the elderly. ..
  53. GENETICS OF ADHD
    Josephine Elia; Fiscal Year: 2007
    ..Dr. Douglas Levinson will provide mentoring in statistical methods and data analyses and Dr. Judith Rapoport will provide mentoring in defining novel phenotypic definitions for ADHD. ..
  54. DVD Consent for Research in Older Schizophrenia Patients
    Dilip Jeste; Fiscal Year: 2008
    ..The DVD-based consent is not intended to supplant, but rather to supplement, the researcher-participant in-person interaction involved in consent process. ..
  55. Frontal White Matter and Impulsivity in Schizophrenia
    Matthew Hoptman; Fiscal Year: 2007
    ..A secondary aim will examine the relationship between FA and violence. Understanding the neural basis of impulsivity in schizophrenia would help identify at-risk patients and inform new treatment approaches. ..
  56. Novel Glutamatergic Detoxification Strategies
    John Krystal; Fiscal Year: 2006
    ..abstract_text> ..
  57. EMORY COLLABORATIVE CENTER: PD ENVIRONMENTAL RESEARCH
    Mahlon Delong; Fiscal Year: 2007
    ..Each of the projects capitalizes on one or more existing funded projects. This fact, together with the core facilities of the CND allows us to leverage the requested funds for maximal effect...
  58. PEDIATRIC BIPOLAR COLLABORATIVE MOOD STABILZER TRAIL
    Robert Findling; Fiscal Year: 2003
    ..Lastly, this trial will provide descriptive information on the stability of acute phase response to monotherapy over a 16 week continuation phase. ..
  59. PROBING DRUG RELATED MENTAL DISORDERS OF AGING
    Ira Katz; Fiscal Year: 2003
    ..We will also explore the impact of medications on daily reports of positive or negative events and on the relationship between daily events and daily affect. ..
  60. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 2004
    ..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..
  61. AMINO ACID NEUROTRANSMITTER DYSREGULATION IN ALCOHOLISM
    John Krystal; Fiscal Year: 2008
    ..abstract_text> ..